Bailard’s Black Diamond Therapeutics BDTX Stock Holding History

Bailard’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$110K	Buy	+51,500	New	+$122K	﹤0.01%	724
2025 Q3	–	Sell	-15,800	Closed	-$39.2K	–	790
2025 Q2	$39.2K	Buy	+15,800	New	+$30.5K	﹤0.01%	753
2022 Q4	–	Sell	-21,281	Closed	-$36K	–	712
2022 Q3	$36K	Sell	21,281 -37,219	-64%	-$115K	﹤0.01%	653
2022 Q2	$144K	Buy	+58,500	New	+$136K	0.01%	637

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bailard's BDTX Position: Q1 2026 in Review

Bailard opened a new position in Black Diamond Therapeutics (BDTX) in Q1 2026: 51,500 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #724 among its holdings. This is a return to the name: Bailard previously reported a position in BDTX as recently as Q2 2025.

Bailard first reported a position in BDTX in Q2 2022 and has held it in 4 quarters since. The position peaked at $144K in Q2 2022. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Bailard held 51,500 shares of Black Diamond Therapeutics worth $110K as of Q1 2026.
Black Diamond Therapeutics was a new Bailard position in Q1 2026.
Black Diamond Therapeutics made up ﹤0.01% of Bailard's portfolio in Q1 2026, its #724 holding.
Bailard first reported a position in Black Diamond Therapeutics in Q2 2022 and has held it in 4 quarters since.
Bailard's Black Diamond Therapeutics position peaked at $144K in Q2 2022.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.